Key Takeaways CorMedix launched DefenCath in 2024 after FDA approval as the first antimicrobial catheter lock solution.DefenCath generated $78.8M in net revenues in H1 2025, showing early commercial traction.Patent protection through 2033 and U.S. reimbursement access support DefenCath's growth runway.CorMedix’s (CRMD) lead drug, DefenCath (Taurolidine + Heparin), is currently its only marketed product that generates revenues for the company.The FDA approved CorMedix’s DefenCath in late 2023 as the first an ...